Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

NCT01912196 is registered in ClinicalTrials.gov with MSI Methylation Sciences, Inc. as lead sponsor.

NCT NCT01912196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01912196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy
Lead sponsor
MSI Methylation Sciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
September 30, 2015
Enrollment
376 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)